SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories inks licensing pact with Gilead Sciences

12 Jul 2011 Evaluate

Ranbaxy Laboratories, country’s largest drug maker has entered into a licensing agreement with Gilead Sciences to manufacture and market three new HIV/AIDS drugs which are currently in late stage clinical development. Ranbaxy will have the rights to produce and sell generic version of these drugs, under license, in India and other developing nations, after gaining necessary regulatory approvals.

As per the agreement, Ranbaxy will extend its existing relationship with Gilead for anti-retrovirals and have the right to manufacture and market generic equivalent of new products, Elvitegravir, an investigational integrase inhibitor, Cobicistant, an investigational antiretroviral boosting agent and Quad, which combines four Gilead HIV medicines in a ince-daily, single-tablet regimen.

The company posted a net loss from ordinary activities after tax of Rs 52.91 crore for the quarter ended March 31, 2011 as compared to net profit from ordinary activities after tax of Rs 871.80 crore for the corresponding quarter last year. Its total income decreased by 43.25% to Rs 1176.42 crore for the quarter under review from Rs 2073.06 crore in the corresponding previous quarter.

Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×